Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.55 |
| ▸ | SMO | Q99835 | 9/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757485 | 0.86 | TACR1 (0.49) | TACR1SMODHODHTACR3 | |
| SCHEMBL5760285 | 0.84 | SMO (0.46) | TACR1SMOCYP3A4 | |
| SCHEMBL4672291 | 0.79 | TACR1 (0.43) | TACR1SMOCYP3A4 | |
| SCHEMBL5758926 | 0.79 | SMO (0.45) | TACR1SMOCYP3A4 | |
| SCHEMBL6525284 | 0.77 | TACR1 (0.81) | TACR1CYP3A4TACR3 | |
| SCHEMBL1399329 | 0.75 | TACR1 (0.59) | TACR1SMOCYP3A4 | |
| SCHEMBL29514441 | 0.75 | TACR1 (0.59) | TACR1SMOCYP3A4 | |
| SCHEMBL1399464 | 0.74 | TACR1 (0.54) | TACR1CYP3A4 | |
| SCHEMBL7137826 | 0.74 | TACR1 (0.47) | TACR1SMO | |
| SCHEMBL905364 | 0.74 | TACR1 (0.57) | TACR1SMOCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247240-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | HOFFMANN TORSTEN | 2006-11-02 | — | — | US | claimed |
| EP-1305319-B1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-04-05 | — | — | EP | claimed |
| EP-1621195-A2 | The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | claimed |
| EP-1406618-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS WITH PYRIDINIC STRUCTURE FOR THE TREATMENT OF BRAIN, SPINAL OR NERVE INJURY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-14 | — | — | EP | claimed |
| US-6624176-B2 | Heteroaromatic substituted amide showing antagonist activity to neurokinin 1 (NK-1, substance P) receptors for nervous system disorders and antidepressants | HOFFMANN-LA ROCHE INC. | 2003-09-23 | — | — | US | claimed |
| US-20030130508-A1 | Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors | HOFFMANN TORSTEN (DE) | 2003-07-10 | — | — | US | claimed |
| EP-1305319-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-02 | — | — | EP | claimed |
| US-20030083345-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-01 | — | — | US | claimed |
| WO-2003006016-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS WITH PYRIDINIC STRUCTURE, FOR THE TREATMENT OF BRAIN, SPINAL OR NERVE INJURY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-23 | — | — | WO | claimed |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | claimed |
| US-20020038030-A1 | Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-03-28 | — | — | US | claimed |
| WO-2002008232-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | claimed |
| US-20110053954-A1 | METHOD OF TREATMENT AND/OR PREVENTION OF BRAIN, SPINAL OR NERVE INJURY | HOFFMANN TORSTEN | 2011-03-03 | — | — | US | disclosed |
| US-20060247240-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | HOFFMANN TORSTEN | 2006-11-02 | — | — | US | disclosed |
| EP-1305319-B1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-04-05 | — | — | EP | disclosed |
| EP-1621195-A2 | The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| WO-2002085458-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. HOFFMAN-LA ROCHE AG (CH) | 2002-10-31 | — | — | WO | disclosed |
| US-20020038030-A1 | Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-03-28 | — | — | US | disclosed |
| WO-2002008232-A1 | 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053954-A1 | METHOD OF TREATMENT AND/OR PREVENTION OF BRAIN, SPINAL OR NERVE INJURY | NTSR1, NTRK2, NMUR1 | TACR1 14/4885SMO 4048/4885CYP3A4 3255/4885 |
| US-20030130508-A1 | Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors | TACR1, NPSR1, TACR2 | TACR1 1/4885SMO 2815/4885CYP3A4 1538/4885 |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | KLK3, TACR1, TACR2 | TACR1 2/4885SMO 3420/4885CYP3A4 1133/4885 |
| US-20030083345-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | NTRK2, NTSR1, NMUR1 | TACR1 9/4885SMO 4381/4885CYP3A4 3268/4885 |
| US-20060247240-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | NTSR1, NTRK2, NMUR1 | TACR1 10/4885SMO 4145/4885CYP3A4 3267/4885 |
| US-20020038030-A1 | Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors | TACR1, NPSR1, TACR2 | TACR1 1/4885SMO 2815/4885CYP3A4 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.